Cargando…

Retrospective comparison of the different immune combinations in metastatic renal cell carcinoma

Detalles Bibliográficos
Autores principales:	Grünwald, Viktor, Panic, Andrej
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7396258/ https://www.ncbi.nlm.nih.gov/pubmed/32793684 http://dx.doi.org/10.21037/atm.2020.02.179

Ejemplares similares

First Line Medical Treatment of Metastatic Renal Cell Carcinoma: A Podcast on Choosing Wisely and Managing Safely
por: Ivanyi, Philipp, et al.
Publicado: (2023)

A Podcast Discussion on the Current Treatment Landscape for Renal Cell Carcinoma
por: Ivanyi, Philipp, et al.
Publicado: (2023)

Health-Related Quality of Life as a Prognostic Measure of Clinical Outcomes in Renal Cell Carcinoma: A Review of the CheckMate 025 Trial
por: Grimm, Marc-Oliver, et al.
Publicado: (2017)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Predictive Factors for Second-Line Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Analysis
por: Eggers, Hendrik, et al.
Publicado: (2017)

Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
por: Minervini, Andrea, et al.
Publicado: (2019)

Management of metastatic renal cell carcinoma: The complexity of choice
por: Brown, Jacqueline T., et al.
Publicado: (2019)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Systemic therapy in metastatic renal cell carcinoma
por: Bedke, Jens, et al.
Publicado: (2016)

The prospect of combination therapy with immune checkpoint inhibitors and chemotherapy for squamous cell carcinoma of the lung
por: Ichiki, Yoshinobu, et al.
Publicado: (2020)

Live bacterial supplementation for improving treatment response in metastatic renal cell carcinoma
por: Meza, Luis, et al.
Publicado: (2022)

Update on the treatment of metastatic renal cell carcinoma
por: Medina López, Rafael Antonio, et al.
Publicado: (2022)

Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor
por: Ornstein, Moshe C., et al.
Publicado: (2023)

First-line immune checkpoint inhibitors for patients with metastatic urothelial carcinoma treated in routine clinical practice
por: Naito, Renato, et al.
Publicado: (2020)

Prognostic models in papillary renal cell carcinoma
por: Attalla, Kyrollis, et al.
Publicado: (2020)

VENUSS rising for papillary renal cell carcinoma prognostication?
por: Buchler, Tomas
Publicado: (2020)

Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler‐Weber‐Rendu Syndrome
por: Hahn, Andrew W., et al.
Publicado: (2018)

Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma
por: Shao, Zhiying, et al.
Publicado: (2016)

Routine Bone Imaging for Metastatic Renal Cell Carcinoma: Is it Time?
por: Parikh, Mamta
Publicado: (2021)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

Tumour response in metastatic renal cell carcinoma treated with tyrosine kinase inhibitors – assessment of intra-tumour heterogeneity
por: Stühler, Viktoria, et al.
Publicado: (2016)

Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
por: Walther, Thomas, et al.
Publicado: (2021)

Long-term efficacy of immune checkpoint inhibitors with or without chemotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a commentary on the 4-year follow-up of the KEYNOTE-048 trial
por: Sano, Daisuke, et al.
Publicado: (2023)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Cabozantinib: an Active Novel Multikinase Inhibitor in Renal Cell Carcinoma
por: Tannir, Nizar M., et al.
Publicado: (2017)

Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
por: Donskov, Frede
Publicado: (2021)

Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma
por: Busch, Jonas, et al.
Publicado: (2011)

Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma
por: Lee, Chung-Han, et al.
Publicado: (2018)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2023)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Systemic treatment of advanced/metastatic renal cell carcinoma in the context of SARS-CoV-2 pandemic: recommendations from the interdisciplinary working group for renal tumors (IAG-N)
por: Ivanyi, Philipp, et al.
Publicado: (2020)

Immune combinations and complete response: a new hope for metastatic renal cell carcinoma
por: Catalano, Martina, et al.
Publicado: (2022)

Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma
por: Saal, Jonas, et al.
Publicado: (2023)

Behind a personalized therapy with immune check-point inhibitors in metastatic bladder cancer: ready for a primetime?
por: Poletajew, Sławomir, et al.
Publicado: (2020)

Combination of immunotherapy with chemotherapy in first line treatment of metastatic gastric cancer? Too much, too little or just right?
por: Ng, Matthew C. H., et al.
Publicado: (2020)

Editorial Comment to A case of sarcoidosis‐like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Kijima, Toshiki
Publicado: (2021)

Advancing the diagnosis and classification of renal cell carcinomas
por: Rothwell, Joseph A.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_plium4dhrejoh01oh53mb7i4jb